Median OS was not reached with TECENTRIQ + Avastin vs 13.2 months with sorafenib (HR=0.58; 95% CI, 0.42, 0.79; P=0.0006) 1

NCCN Category 2A Preferred

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend atezolizumab (TECENTRIQ) in combination with bevacizumab (Avastin) as a preferred first-line systemic therapy for patients with unresectable or metastatic hepatocellular carcinoma (Child-Pugh Class A) 2*

View the full TECENTRIQ Prescribing Information

Find information on financial assistance programs for eligible TECENTRIQ patients

1L=first line; CI=confidence interval; HCC=hepatocellular carcinoma; HR=hazard ratio; NCCN=National Comprehensive Cancer Network; OS=overall survival.
*Category 2A: based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Preferred intervention: interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.